NCT06364150View on ClinicalTrials.gov

Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

August 1, 2026

Conditions
Acute Myocardial Infarction
Interventions
BIOLOGICAL

Autologous Peripheral Blood Stem Cell injection

For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

lead

Seoul National Hospital

OTHER_GOV